F
Federica Maritati
Researcher at University of Parma
Publications - 44
Citations - 1151
Federica Maritati is an academic researcher from University of Parma. The author has contributed to research in topics: Granulomatosis with polyangiitis & Vasculitis. The author has an hindex of 16, co-authored 39 publications receiving 754 citations. Previous affiliations of Federica Maritati include University of Bologna & University of Florence.
Papers
More filters
Journal ArticleDOI
IgG4 immune response in Churg–Strauss syndrome
Augusto Vaglio,Johanna D Strehl,Bernhard Manger,Federica Maritati,Federico Alberici,Christian Beyer,Jürgen Rech,Renato Alberto Sinico,Francesco Bonatti,Luisita Battistelli,Jörg H W Distler,Georg Schett,Jochen Zwerina +12 more
TL;DR: Serum IgG4 levels are markedly elevated in active CSS and correlate with the number of organ manifestations and disease activity and longitudinal analysis in 12 CSS cases showed that both the IgG3 level and IgG 4/IgG ratio dropped during disease remission.
Journal ArticleDOI
Eosinophilic granulomatosis with polyangiitis: an overview.
TL;DR: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disorder, belonging to the small vessel anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, defined as an eOSinophil-rich and necrotizing granulOMatous inflammation often involving the respiratory tract, and Necrotizing vasculopathy predominantly affecting small to medium-sized vessels.
Journal ArticleDOI
Idiopathic Retroperitoneal Fibrosis
Augusto Vaglio,Federica Maritati +1 more
TL;DR: Idiopathic retroperitoneal fibrosis (RPF) as discussed by the authors is a rare fibro-inflammatory disease that develops around the abdominal aorta and the iliac arteries, and spreads into the adjacent retinalum, where it frequently causes ureteral obstruction and renal failure.
Journal ArticleDOI
IgG4-related disease: a clinical perspective.
TL;DR: The first-line treatment of IgG4-RD is based on glucocorticoids, which are usually efficacious, but B cell depletion induced by rituximab has also been found to induce remission in steroid-resistant disease or has been used as steroid-sparing agent for relapsing disease.
Journal ArticleDOI
Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein)
Federica Maritati,Roberta Fenoglio,Evangeline Pillebout,Giacomo Emmi,Maria Letizia Urban,Rossana Rocco,Maria Nicastro,Monia Incerti,Matteo Goldoni,Giorgio Trivioli,Elena Silvestri,Aladdin J Mohammad,David Jayne,Per Eriksson,Mårten Segelmark,Pavel Novikov,Helen Harris,Dario Roccatello,Augusto Vaglio +18 more
TL;DR: Rituximab (RTX) is a B cell–depleting antibody of proven efficacy in antineutrophil cytoplasmic antibody–associated vasculitis and the efficacy and safety of RTX were tested in a multicenter cohort of patients with adult‐onset IgAV.